JAMA Oncol:诊断乳腺癌后何时手术?手术后何时化疗?

2015-12-11 MedSci MedSci原创

 JAMA Oncology上两篇文章阐述了乳腺癌患者手术和化疗时机与生存间联系。第一篇研究,来自德克萨斯大学MD安德森癌症中心的Mariana Chavez-MacGregor分析了24,843例浸润性乳腺癌(Ⅰ-Ⅲ期)数据,探究术后化疗时机和总生存以及乳腺癌相关生存间联系,同时识别与推迟化疗相关因素。纳入的24,843名患者,平均年龄53岁,术后开始化疗中位数时间是46天。21%的患

JAMA Oncology上两篇文章阐述了乳腺癌患者手术和化疗时机与生存间联系。第一篇研究,来自德克萨斯大学MD安德森癌症中心的Mariana Chavez-MacGregor分析了24,843例浸润性乳腺癌(Ⅰ-Ⅲ期)数据,探究术后化疗时机和总生存以及乳腺癌相关生存间联系,同时识别与推迟化疗相关因素。

纳入的24,843名患者,平均年龄53岁,术后开始化疗中位数时间是46天。21%的患者不到31天就开始化疗,50%的患者在31-60天间开始化疗,19.2%的患者在61-90天内开始化疗,还有9.8%的患者术后超过91天才开始化疗。导致化疗推迟的因素有社会经济地位低、乳房重建、非私人保险、西班牙裔或黑人。

术后31-90天内化疗与术后31天内开始化疗的患者相比,没有发现不良预后。不过术后超过91天才开始化疗的患者其总生存和乳腺癌相关生存更差;该类患者总死亡风险增加34%,因乳腺癌死亡风险增加27%!三阴乳腺癌患者术后超过91天才开始化疗同样总生存和乳腺癌相关生存更差。不过该回顾性研究使用的是历史数据,存在一定限制。

第二篇研究,来自美国癌症中心Fox Chase的Richard J. Bleicher及同事分析了美国最大的两个癌症数据库,探究从诊断乳腺癌到手术的时间与生存的关系。分析的第一个数据库纳入了95,544名患者,绝大部分为女性,平均年龄75岁。诊断后30天内手术的占77.7%;31-60天手术的有18.3%;61-90天手术的有2.7%;91-120天手术的有0.7%;诊断后120-180天才手术的有0.5%。数据分析显示,从诊断到手术期间时间间隔每增加一个范围,患者全因死亡风险增加9%。随时间延长总生存下降,尤其是Ⅰ、Ⅱ期乳腺癌患者。间隔增加60天,死亡风险增加,尤其是对Ⅰ期乳腺癌患者。

研究者分析了另一个数据库,共95,544名患者,几乎全部是女性,平均60岁。诊断到手术间隔小于30天的有69.5%,31-60天有24.9%,61-90天有4.1%,91-120天有1%,121-180天有0.5%。时间间隔每增加一个范围,全因死亡风险增加10%,尤其是对Ⅰ、Ⅱ期乳腺癌患者。总的来说,早期乳腺癌患者的生存与否更容易受诊断到术后时间间隔的影响。

原始出处:

Mariana Chavez-MacGregor, Christina A. Clarke, et al.Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.JAMA Oncol. Published online December 10, 2015.

Richard J. Bleicher,  Karen Ruth, et al.Time to Surgery and Breast Cancer Survival in the United States.JAMA Oncol. Published online December 10, 2015.

Survival and time to surgery, chemotherapy for patients with breast cancer

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=95615, encodeId=425b956151e, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:49:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864747, encodeId=b83b1864e4778, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 24 11:48:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48502, encodeId=913a48502bd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45841, encodeId=bfcf4584104, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45788, encodeId=768445e88c9, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:29:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45741, encodeId=e06945e413e, content=尽早手术,尽早化疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 12 23:27:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-08-03 1dd8c52fm63(暂无匿称)

    了解一下!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=95615, encodeId=425b956151e, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:49:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864747, encodeId=b83b1864e4778, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 24 11:48:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48502, encodeId=913a48502bd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45841, encodeId=bfcf4584104, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45788, encodeId=768445e88c9, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:29:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45741, encodeId=e06945e413e, content=尽早手术,尽早化疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 12 23:27:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-09-24 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=95615, encodeId=425b956151e, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:49:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864747, encodeId=b83b1864e4778, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 24 11:48:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48502, encodeId=913a48502bd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45841, encodeId=bfcf4584104, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45788, encodeId=768445e88c9, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:29:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45741, encodeId=e06945e413e, content=尽早手术,尽早化疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 12 23:27:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=95615, encodeId=425b956151e, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:49:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864747, encodeId=b83b1864e4778, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 24 11:48:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48502, encodeId=913a48502bd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45841, encodeId=bfcf4584104, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45788, encodeId=768445e88c9, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:29:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45741, encodeId=e06945e413e, content=尽早手术,尽早化疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 12 23:27:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-13 yuwenpsy

    ………

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=95615, encodeId=425b956151e, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:49:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864747, encodeId=b83b1864e4778, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 24 11:48:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48502, encodeId=913a48502bd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45841, encodeId=bfcf4584104, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45788, encodeId=768445e88c9, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:29:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45741, encodeId=e06945e413e, content=尽早手术,尽早化疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 12 23:27:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-13 yuwenpsy

    …………

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=95615, encodeId=425b956151e, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:49:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864747, encodeId=b83b1864e4778, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 24 11:48:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48502, encodeId=913a48502bd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45841, encodeId=bfcf4584104, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45788, encodeId=768445e88c9, content=…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:29:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45741, encodeId=e06945e413e, content=尽早手术,尽早化疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 12 23:27:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-12 jetleo

    尽早手术,尽早化疗。

    0

相关资讯

SABCS 15:ONT-380治疗转移性HER2+乳腺癌疗效卓越!(圣安东尼奥乳癌研讨会)

2015年圣安东尼奥乳癌研讨会上报道了正在进行的1b临床试验,关于抗癌药物ONT-380治疗转移性HER2+乳腺癌,尤其是脑转移(通常意味着疾病恶化进展)。研究共纳入33名转移性HER2+乳腺癌患者(伴或不伴脑转移),使用抗癌药物ONT-380治疗后,19(58%)名患者表现出了显著疗效,16名患者起码达到了“疾病稳定”(试验中疾病无进展),其中11名部分缓解(肿瘤缩小30%以上)。8名脑转移患者

SABCS 2015:10年数据表明,早期乳癌选择保乳术+放疗优于乳房切除术

2015年圣安东尼奥乳癌研讨会上提供的数据表明,早期乳癌患者选择保乳术+放疗(BCT)与乳房切除术(不加放疗)相比,可显著改善10年后总生存。先前有观察性研究表明早期乳癌患者选择BCT比乳房切除术有更好的生存,但是这些观察性研究都有各自限制,绝大部分研究最多随访了5年时间而已。因此该结论是否具有广泛性还需要进一步大样本长期预后的随访。Siesling和同事根据荷兰癌症相关数据,纳入2000-200

BMJ研究新闻:好奇怪!5/6的乳腺癌高危女性拒绝预防性用药

据发表于Annals of Oncology的一项新的研究表明,六分之五的乳腺癌高危女性拒绝服用可降低其乳腺癌发病风险的药物。

FDA批准一种能预防化疗脱发的帽子

FDA批准预防化疗脱发的帽子接受化疗的乳腺癌患者很快便可获得一个防止脱发的新选择:一种特殊的帽子,可在患者接受化疗时冷却其头皮。本周二,FDA批准了这种特殊帽子(DigniCap)的应用。冷却头皮上的血管可降低化疗药物到达毛囊的水平。目前市场上销售的这种帽子的是瑞典的一家公司Dignitana所生产的, Dignitana称这是FDA批准的第一个用于冷却头皮的帽子。DigniCap是如何工作的?临

SABCS 2015:化疗对Luminal A型乳腺癌无益?!附评论(圣安东尼奥乳癌研讨会)

对以前的Danish研究的最新分析表明,绝经前女性患Luminal A 型乳腺癌(一种常见的固有亚型),就算淋巴结已转移,可以完全不使用化疗,也能有较好预后!加拿大英属哥伦比亚大学的Torsten Nielsen在正在举行的圣安东尼奥乳腺癌研讨会上报道了数据分析结果,引起了一些非议,毕竟化疗对于绝经前乳腺癌女性是标准治疗方案。圣安东尼奥德克萨斯大学健康科学中心的Virginia Kaklamani